Structure-activity relationship studies of isoquinolinone type anticancer agent

Archives of Pharmacal Research

Volumn 24, Issue 4, 2001, Pages 276-280

  Cheon, Seung Hoon ^a   Park, Joon Suck ^a   Lee, Joon Yeol ^a   Lee, You Na ^a   Yi, Hyo ^a   Chung, Byung Ho ^a   Choi, Bo Gil ^a   Cho, Won Jea ^a   Choi, Sang Un ^b   Lee, Chong Ock ^b  

^a Chonnam National University   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

3 biphenylisoquinolin 1 ones; Anticancer; Cytotoxicity; Isoquinolin 1 ones

Indexed keywords

ANTINEOPLASTIC AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; ISOQUINOLINE DERIVATIVE;

ARTICLE; CELL CULTURE; DRUG SCREENING; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDICATORS AND REAGENTS; ISOQUINOLINES; MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0035430307     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02975091     Document Type: Article

References (25)

1. Berdel, W. E. and Munder, P. G., Antitumor Analogs of PAF, In Snyder, F. (Ed). Platelet-Activating Factor and Related Lipid Mediators. Plenum Press, New York, pp. 449-467, 1987.
2. Berry, J. M. and Threadgill, M. D., Labeled compounds of interest as antitumor agents. V. Syntheses of [18O]-5-methylisoquinolinone and 1-(furan-2-yl-[18O]-methoxy) -5-methylisoquinoline. J. Labelled Compd. Radiopharm., 38, 935-940 (1996).
3. Brunton, V. G. and Workman, P., Br. J. Cancer, 67, 989 (1993).
4. Cheon, S. H., Park, J. S., Jeong, S. H., Chung, B. H., Choi, B. G., Cho, W. J., Kang, B. H., and Lee, C. O., Synthesis and Structure-Activity Relationship Studies of 2,3-Dihydroimidazo[2,1-a]isoquinoline Analogs as Antitumor Agents. Arch. Pharm. Res., 20, 138-143 (1997).
5. Cheon, S. H., Park, J. S., Chung, B. H., Choi, B. G., Cho, W. J., Choi, S. U., and Lee, C. O., Synthesis and structure-activity relationship studies of substituted isoquinoline analogs as antitumor agent. Arch. Pharm. Res., 21, 193-197 (1998).
6. Cheon, S. H., Lee, J. Y., Chung, B. H., Choi, B. G., Cho, W. J., and Kim, T. S., Studies on the synthesis and in vitro antitumor activity of the isoquinolone derivatives, ynthesis and structure-activity relationship studies of substituted isoquinoline analogs as antitumor agent. Arch. Pharm. Res., 22, 179-183 (1999).
7. Cho, W. J., Yoo, S. J., Chung, B. H., Choi, B. G., Cheon, S. H., Whang, S. H., Kim, S. K., Kang, B. H., and Lee, C. O., Synthesis of Benzo[c]phenanthridine Derivatives and their in Vitro Antitumor Activities. Arch. Pharm. Res., 19, 321-325 (1996).
8. Danhauser-Riedl, S., Felix, S. B., Houlihan, W. J., Zafferani, M., Steinhauser, C., Oberberg, D., Kalvelage, H., Busch, R., Rastetter, J., and Berdel, W. F., Cancer Res., 51, 43 (1991)
9. Dive, C., Watson, J. V., and Workman, P., Multiparametric Flow Cytometry of the Modulation of Tumor Cell Membrane Permeability by Developmental Antitumor Ether Lipid SRI 62-834 in EMT6 Mouse Mammary Tumor and HL6O Human Promyelocytic Leukemia cells. Cancer Res., 51, 799-806 (1990).
10. Houlihan, W. J. and Parrino, V. A., Directed Lithiation of 2-Phenyl- and 2-(o-methylphenyl)imidazoline. J. Org. Chem., 47, 5177-5180 (1982).
11. Houlihan, W. J., Cheon, S. H., Parrino, V. A., Handley, D. A., and Larson, D. A., Structural Modification of 5-Aryl-2,3-dihydroimidazo[2,1-a]isoquinoline Platelet Activating Factor Receptor Antagonists. J. Med. Chem., 36, 3098-3102 (1993).
12. Houlihan, W. J., Munder, P. G., Handley, D. A., Cheon, S. H., and Parrino, V. A., Antitumor Activity of 5-Aryl-2,3-dihydroimidazo[2,1-a]isoquinolines. J. Med. Chem., 38, 234-240 (1995a).
13. Houlihan, W. J., Munder, P. G., Handley, D. A., and Nemecek, G. A., Priclinical Pharmacology and Possible Mechanism of Action of the Novel Antitumor Agent 5-(4′-Piperidinomethylphenyl)-2,3-dihydroimidazo[2,1-a]isoquinoline. Arzneim.-Forsch./Drug Res., 45(II), 1133-1137 (1995b).
14. Hutchinson, J. H., Cook, J. J., Brashear, K. M., Breslin, M. J., Glass, J. D., Gould, R. J., Halczenko, W., Holahan, M. A., and Lynch, R. J., Non-peptide glycoprotein IIb/ IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1(1H)-isoquinolinone-based antagonists and ethyl ester prodrugs. J. Med. Chem., 39, 4583-4591 (1996).
15. Modest, E. J., Berens, M. E., Piantadosi, C., and Noseda, A., Pharmacological Effects and Anticancer Activity of New Ether Phospholipid Analogs, In Kabara J. J. (Ed). The Pharmacological Effect of lipids III, Role of Lipids in Cancer Research. The American Oil Chemists' Society, Champaign, IL, pp. 330-337, 1989.
16. Munder, P. G. and Westphal, O., Antitumoral and Other Biomedical Activities of Synthetic Ether Lysophospholipids, In Waksman, B. H. (Ed). 1939-1989: Fifty Years Progress in Allergy. Karger, New York, pp. 206-235, 1990.
17. Noseda, A., Godwin, P. L., and Modest, E. J., Effects of Antineoplastic Ether Lipids on Model and Biological Membranes, Biochim. Biophys. Acta, 945, 92-100 (1988).
18. Poindexter, G. S., Convenient preparation of 3′-substituted-1(2H)-isoquinolines. J. Org. Chem., 47, 3787-3788 (1982).
19. Rubinstein, L. V., Shoemaker, R. H., Paul, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D., Monks, A., and Boyd, M. R., J. Natl. Cancer Inst., 82, 1113 (1990).
20. 2+ Signaling by Antitumor Ether Lipid Analogues. Cancer Res., 50, 4458-4463 (1990).
21. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J. B., Vistica, D. T., Warren, J. T., Bokesch, H., Kenny, S., and Boyd, M. R., J. Natl. Cancer Inst., 82, 1107 (1990).
22. Still, W. C., Kahn, M., and Mitra, A. J., J. Org. Chem., 43, 2923 (1978)
23. Uberall, F., Oberhuber, H., Maly, K., Zaknun J., Demuth, L., and Grunicke, H. H., Hexadecylphosphocholine Inhibits Inositol Phosphate Formation and Protein Kinase C Activity. Cancer Res., 51, 807-812 (1991).
24. Watson, C. Y., Whish, W. J. D., Treadgill, M. D., Synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1(2H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP). Bioorg. Med. Chem., 6, 721-734 (1998).
25. Workman, P., Antitumor Ether Lipids: Endocytosis as a Determination of Cellular Sensitivity. Cancer Cells, 3, 315-317 (1991).